High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.